Evidence map›Paper›PMID 26248366›Full record

ArticleAntimicrobial agents and chemotherapy2015

Antimicrobial Susceptibility and SOS-Dependent Increase in Mutation Frequency Are Impacted by Escherichia coli Topoisomerase I C-Terminal Point Mutation.

Jenny Yang, Thirunavukkarasu Annamalai, Bokun Cheng, Srikanth Banda, Rakhi Tyagi, Yuk-Ching Tse-Dinh

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Bacterial Topoisomerase I Growth Complementation Assay.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Using rapid point-of-care tests to inform antibiotic choice to mitigate drug resistance in gonorrhoea.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020
    Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jenny YangDepartment of Biochemistry and Molecular Biology, New York Medical College, Valhalla, New York, USA.
Thirunavukkarasu AnnamalaiDepartment of Chemistry and Biochemistry, Florida International University, Miami, Florida, USA.
Bokun ChengDepartment of Biochemistry and Molecular Biology, New York Medical College, Valhalla, New York, USA.
Srikanth BandaDepartment of Chemistry and Biochemistry, Florida International University, Miami, Florida, USA.
Rakhi TyagiDepartment of Biochemistry and Molecular Biology, New York Medical College, Valhalla, New York, USA.
Yuk-Ching Tse-DinhDepartment of Chemistry and Biochemistry, Florida International University, Miami, Florida, USA Biomolecular Sciences Institute, Florida International University, Miami, Florida, USA yukching.tsedinh@fiu.edu.
Florida International University · USNew York Medical College · US

Funding

Supplement for undergraduate research participant to promote diversityR01GM054226 · NIGMS · NEW YORK MEDICAL COLLEGE · PI TSE-DINH, YUK-CHING · 1996 to 2020
$4.6M
Bacterial cell killing topoisomerase I--DNA lesionR01AI069313 · NIAID · NEW YORK MEDICAL COLLEGE · PI TSE-DINH, YUK-CHING · 2006 to 2014
$3.4M
NIAID NIH HHS R01 AI069313NIAID NIH HHS R01AI069313NIGMS NIH HHS R01 GM054226NIGMS NIH HHS R01GM054226
6 · The paper itself

Abstract

Topoisomerase functions are required in all organisms for many vital cellular processes, including transcription elongation. The C terminus domains (CTD) of Escherichia coli topoisomerase I interact directly with RNA polymerase to remove transcription-driven negative supercoiling behind the RNA polymerase complex. This interaction prevents inhibition of transcription elongation from hypernegative supercoiling and R-loop accumulation. The physiological function of bacterial topoisomerase I in transcription is especially important for a rapid network response to an antibiotic challenge. In this study, Escherichia coli with a topA66 single nucleotide deletion mutation, which results in a frameshift in the TopA CTD, was shown to exhibit increased sensitivity to trimethoprim and quinolone antimicrobials. The topoisomerase I-RNA polymerase interaction and the SOS response to the antimicrobial agents were found to be significantly reduced by this topA66 mutation. Consequently, the mutation frequency measured by rifampin selection following SOS induction was diminished in the topA66 mutant. The increased antibiotic sensitivity for the topA66 mutant can be reversed by the expression of recombinant E. coli topoisomerase I but not by the expression of recombinant Mycobacterium tuberculosis topoisomerase I that has a nonhomologous CTD even though the recombinant M. tuberculosis topoisomerase I can restore most of the plasmid DNA linking number deficiency caused by the topA66 mutation. Direct interactions of E. coli topoisomerase I as part of transcription complexes are likely to be required for the rapid network response to an antibiotic challenge. Inhibitors of bacterial topoisomerase I functions and interactions may sensitize pathogens to antibiotic treatment and limit the mutagenic response.

Indexed as

Frameshift MutationGene Expression Regulation, BacterialAnti-Bacterial AgentsDNA-Directed RNA PolymerasesDNA Topoisomerases, Type IEscherichia coliEscherichia coli ProteinsGenetic Complementation TestMicrobial Sensitivity TestsMutation RateMycobacterium tuberculosisPlasmidsProtein BindingProtein Structure, TertiaryQuinolonesRecombinant ProteinsAnti-Bacterial AgentsDNA-Directed RNA PolymerasesDNA Topoisomerases, Type IEscherichia coli ProteinsQuinolonesRecombinant ProteinsRifampinTrimethoprim

Identifiers

PMID26248366
PMCPMC4576087
OpenAlexW1894706304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.